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We have studied our experience since 1988 with 31 patients who required a 
mechanical circulatory bridge to transplantation and also had biventricular 
failure (mean right ventricular ejection fraction 11.8%) to better define the 
need for biventricular or total artificial heart support versus univentricular 
support. Clinical factors including preoperative inotropic need, fever without 
detectable infection, diffuse radiographic pulmonary edema, postoperative 
blood transfusion, and right ventricular wall thickness were compared with 
hemodynamic parameters including cardiac index, right ventricular ejectio n
fraction, central venous pressure, mean pulmonary arterial pressure, and total 
pulmonary resistance for ability to predict need for mechanical or high-dos e 
inotropic support for the right ventricle. Patients were grouped according to 
need for right ventricular support after left ventricular-assist device implan- 
tation: none (group A, 14) inotroPic drugs (group Ba, 7), and right ventricle 
mechanical support (group B2, 10). There were no differences in preimplan- 
tation hemodynamic variables. Groups B l and B2 had significantly lower 
mixed venous oxygen saturation (39.2% vs 52.5% in group A; p < 0.001), 
greater level of inotropic need (p < 0.02), greater impairment of mental status, 
and lower ratio of right ventricular ejection fraction to inotropic need (0.37 vs 
0.56 for group A; p < 0.02) before left ventricular-assist device implantation. 
A significant discriminator between groups B1 and B2 was the presence of a 
fever without infection within i0 days of left ventrieular-assist device implan, 
tation (43% in group B 1 vs 70% in group B2). Group B2 had more patients with 
preimplantation pulmonary edema seen on chest radiography and a greater 
requirement for postoperative blood transfusion (5 units of cells in group B i vs 
14.8 units in group B2. Right ventricular wall thickness at left ventricular- 
assist device explantation was 0.83 cm in group B z vs 0.44 cm in group B 1 (p < 
0.05). Transplantation rates after bridging were 100% in group A, 71% in group 
Ul, and 40% in group B z. Clinical factors that reflect preimplantation degree of 
illness and perioperative factors that result in impairment of pulmonary blood 
flow or reduced perfusion of the right ventricle after left ventricular-assist 
device implantation are now considered to be more predictive of the need for 
additional right ventricular support han preimplantation measures of right 
ventricular function or hemodynamic variables. (J TrIORAC CARDIOVASC SURG 
1996;111:773-83) 
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C linical trials with left ventricular-assist devices (LVADs) as bridges to cardiac transplantation 
continue to suggest a potential role for such devices 
13 as an alternative to cardiac transplantation. " Be- 
fore applicability of such devices in this role can be 
assumed, however, a more complete understanding 
of the target population must be demonstrated. 
PerhaPS the least answered question in this respect 
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relates to the selection of patients on the basis of 
adequacy of right ventricular performance. This is a 
particularly difficult dilemma because no preimplan- 
tation criteria as yet exist for predicting the postim- 
plantation performance of the right ventricle in 
hearts supported by LVADs. 4' 5 
Initial reports from our institution were optimistic 
in the hope that most patients with end-stage heart 
failure could survive with univentricular support 
alone. 6'7 Unfortunately there is a 10% to 30% 
reported incidence of right ventricular failure neces- 
sitating right ventricular mechanical support in ad- 
dition to the LVAD, with a mortality rate in this 
setting of 30% to 50%. s Some reports have acknowl- 
edged that right and left ventricular size, ventricular 
filling pressures, ventricular ejection fractions, and 
standard hemodynamic parameters are incapable of 
Predicting which patients are at risk for inadequate 
right ventricular performance to support adequate 
LVAD cardiac output, 3 whereas others have sug- 
gested that a right atrial pressure greater than 20 
mm Hg predicts the need for biventricular assis- 
tance. 9 Farrar and coworkers 1° recently reported 
results with 105 left and 195 biventricular Thoratec 
ventricular-assist devices (Thoratec Laboratories 
Corp., Berkeley, Calif.) showing that preassist car- 
diac indexes were lower among persons requiring 
biventricular support and that preimplantation se- 
rum creatinine levels were higherJ ° In addition, 
they showed that a greater percentage of patients 
who underwent biventricular support were receiving 
mechanical ventilation before support, and more 
had implantation in an emergency setting than 
among patients who had the LVAD alone. From our 
early observations, we suspected that clinical events 
surrounding LVAD implantation may be more pre- 
dictive of the success of univentricular support han 
any preoperative functional or hemodynamic mea- 
surement. This report documents our review of 
hemodynamic, physiologic, and clinical data col- 
lected for patients receiving the Novacor left ven- 
tricnlar-assist ystem (LVAS; Novacor Medical Di- 
vision, Baxter Healthcare Corp., Oakland, Calif.) as 
a bridge to cardiac transplantation. Our goal was to 
identify variables that may be predictive of subse- 
quent right ventricular failure. 
Materials and methods 
Patient selection. Between May 1988 and March 1994, 
43 candidates for orthotopic transplantation could not be 
adequately supported hemodynamically b  multiple ino- 
tropic agents and an intraaortic balloon pump (IABP) 
before cardiac transplantation and required additional 
support from the Novacor N-100 LVAS as a bridge to 
transplantation. Thirty-three received the console-based 
system and 10 received the wearable, portable device. 
Patient selection criteria, description of the device, im- 
plantation technique, management, and indications for 
transplantation were published previously. 7 Detailed and 
complete prospective data were available for the last 40 of 
43 consecutive patients (93%); these data form the basis 
for this report. There were 37 male and three female 
patients, ranging in age from 15 to 63 years (mean 43.6 
years). Thirteen patients had ischemic cardiomyopathy 
and 27 had idiopathic dilated cardiomyopathy. The body 
surface area of the patients ranged from 1.5 to 2.3 m 2 
(mean 1.9 m2). All patients required two or more inotro- 
pic agents, and all but nine required an IABP before 
LVAS insertion. An IABP was not inserted in the pres- 
ence of severe supraventricular o ventricular arrhyth- 
rajas, which made IABP timing nearly impossible. Aver- 
age durations of inotropic support and IABP support were 
24 days(range 2 to 71 days) and 11 (range 1 to 43 days), 
respectively. 
All consent forms, implantation techniques, and proto- 
cols for hemodynamic and biomechanical evaluation were 
examined and approved by the University of Pittsburgh 
Institutional Review Board. An investigational device 
exemption was granted by the Food and Drug Adminis- 
tration for the original console-based system in July 1987 
and for the wearable portable system in March 1993. 
Informed consent was obtained from all patients or next 
of kin. All patients who received support were candidates 
for orthotopic transplantation a d underwent such trans- 
plantation as soon as a donor organ could be found and it 
was clear that there were no contraindications to trans- 
plantation. 
Hemodynamic data. Immediately before induction of 
anesthesia for LVAS implantation, a rapid-response ther- 
modilution catheter (REF catheter; Bentley Division; 
Baxter Healthcare Corp., Irvine, Calif.) was placed into 
the pulmonary artery through the right or left internal 
jugular vein. A baseline hemodynamic profile consisting of 
mean arterial pressure, heart rate, mean pulmonary artery 
pressure, and pulmonary capillary wedge pressure was 
obtained. The cardiac output computer provided right 
ventricular ejection fraction (RVEF), right ventricular 
end-diastolic and end-systolic volumes, right ventricular 
stroke volume, right ventricular stroke work index, and 
cardiac output, from which cardiac index was calculated. 
The RVEF measurement was confirmed by calculating 
right ventricular f actional area change obtained by trans- 
esophageal echocardiography with epicardial two-dimen- 
sional images recorded with a Hewlett Packard Sonos 
1500 Ultra Sound System with automated border-detec- 
tion capabilities (model 77035A; Hewlett Packard Co., 
Medical Products Group, Andover, Mass.). Total pulmo- 
nary resistance was calculated by multiplying the mean 
pulmonary artery pressure by 80 and dividing the result by 
cardiac output. These measurements were made prospec- 
tively before and after induction of anesthesia and at 20, 
40, and 60 minutes after the LVAS was started. They were 
repeated at the time of sternal closure and at 8, 24, and 48 
hours after startup. At least hree separate measurements 
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were made and averaged for each data record. Trans- 
esophageal echocardiography was also employed intraop- 
eratively to assess proper implantation technique. 
Clinical data. Clinical data was recorded prospectively 
from patient charts including intensive care unit and 
anesthesia records. An attempt was made to standardize 
the amount of inotropic support needed for right ventric- 
ular support before and after implantation of the LVAS. 
The inotropic levels were expressed as inotropic equiva- 
lents (IEs), with 1 txg-kg -1.  min 1 dopamine, dobut- 
amine, or amrinone equal to 1 IE, 1 /xg • kg -1 • rain -1 
milrinone equal to 15 IE, and 0.1 /xg. kg -~.  min 1 
epinephrine or norepinephrine r presenting 10 IE. In an 
effort to normalize the IEs needed to support the right 
ventricle before and after LVAS implantation, RVEF 
(obtained by the thermodilution technique) was divided 
by the IEs of support used at each point of measurement 
(RVEF/IE ratio). Patients were classified according to 
pre-LVAS RVEF (greater or less than 20%). In addition, 
they were subcategorized according to the need for large 
amounts of inotropic or mechanical support for the right 
ventricle after LVAS implantation. Right ventricular fail- 
ure after LVAS implantation was defined as the need for 
a right ventricular-assist device, despite inotropic support, 
to maintain the LVAS cardiac index at greater than 2.0 
L • min -1 • m -a. In all cases, an attempt was made to 
manage the right ventricle initially with inotropic agents 
alone; however, a right ventricular-assist device in the 
form of a centrifugal pump (Medtronic Bi0-Medicus, 
Eden Prairie, Minn.) was inserted between 8and 24 hours 
after the initial implant of the LVAS if needed. Mixed 
venous oxygen saturation was obtained from the pulmo- 
nary artery catheter in the intensive care unit and repre- 
sented the last measurement before the decision for 
LVAS implantation or just before transfer to the operat- 
ing room. Preimplantation mental status was expressed by 
a score of 0 to 3 (0, normal; I, mildly confused or drowsy 
but appropriately oriented; 2, drowsy but responding to 
verbal stimuli; 3, drowsy and responding only to pain, or 
intubated). The presence or absence of pulmonary edema 
or diffuse interstitial pulmonary infiltrate noted on the 
most recent preimplantation chest radiograph was re- 
corded retrospectively from a review by an independent 
radiographer. The instances of elevation of body temper- 
ature to greater than 38.0° C before implantation were 
noted, and in the presence of an identifiable source of 
infection appropriate intravenous antibiotic therapy was 
started and completed before device implantation. No 
devices were implanted in the presence of a known 
infection that had not resolved, and a period of at least 10 
days of normothermia was required. Cases of fever alone 
were not considered a contraindication to LVAS implan- 
tation when no identifiable infectious source could be 
identified and repeated blood cultures were sterile. For 
purposes of this study, only occurrences of fever without 
septicemia were recorded. The blood products used peri- 
operatively for LVAS implantation were recorded and 
included units of platelets, fresh-frozen plasma, packed 
erythrocytes, and cryoprecipitate. Recorded amounts in- 
cluded only those amounts transfused before any addi- 
tional surgery for a right ventricular-assist device. Patho- 
logic examination of the explanted heart was made either 
during autopsy at patient death or after orthotopic trans- 
plantation. Right and left ventricular wall thickness and 
any right ventricular hypertrophy and fibrosis were noted. 
Data analysis. Patients were classified into groups on 
the basis of the pre-LVAS RVEF. Only those patients 
with RVEF less than or equal to 20% were statistically 
analyzed with respect to variables that could predict 
subsequent right ventricular failure and the need for right 
ventricular mechanical assistance. Further classification 
was then made on the basis of ease of clinical manage- 
ment of the right ventricle after LVAS implantation: 
group A, short-term inotropic support (less inotropic 
support at 8 hours after implantation than before implan- 
tation); group B 1, high-dose inotropic support (greater 
dosage at 8 hours than before implantation; and group B> 
ultimately requiring mechanical right ventricular support. 
Actuarial survival was calculated with the Kaplan-Meier 
method. Previous work had shown that a critical point in 
the clinical course of these patients occurred at the point 
of sternal closure, with no significant changes occurring 
from then until 8 hours after LVAS implantation or until 
a right ventricular-assist device was needed. For that 
reason, hemodynamics at sternal closure were taken as the 
most representative post-LVAS values. Differences in 
means were tested with paired and unpaired t tests for 
normal data, and nonparametric tests (Mann-Whitney) 
were used in other cases. Comparisons were made be- 
tween group A and B patients and between the subgroups 
B 1 and B 2. The )(2 test was used to test the significance of 
differences in proportions between groups, and the Fish- 
er's Exact Test was used for small sample sizes. Ap  value 
less than 0.05 was taken as the level of significance. 
Statistics were performed with STATISTICA for Win- 
dows (StatSoft, Inc., Tulsa, Okla.). 
Results 
Overall  results. Of 40 patients who underwent 
LVAS implantation, 31 (78%) survived to transplan- 
tation and 27 were discharged (68%). Causes of 
death during device support included persistent 
multiorgan failure (five), cerebral hemorrhage 
(two), infection (one), and technical causes (one). 
Deaths after transplantation were from infection 
(fungal, one; toxoplasmosis, one), acute allograft 
rejection (one), and perforated gastric ulcer (one). 
Actuarial survival after cardiac transplantation after 
LVAS support was 90% at 2 years and 73% at 4 
years. 
Patient outcome according to preimplantation 
RVEF  is shown in Fig. 1. Nine patients had preim- 
plant RVEFs greater than 20% (mean 33.2% _+ 
7.5%). No right ventricular dysfunction was seen as 
a result of LVAS implantation in any patient in this 
group, and inotropic agent usage was reduced within 
24 hours in all cases and was discontinued within an 
average of 8 days. Seven of these patients (78%) 
underwent successful heart transplantation and 
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LVAD PATIENTS (n=40) 
I 
I I 
Biventricular Failure Univentricular Failure 
RVEF<20% (Mean=11.8+3.8%) RVEF>20% (Mean=33.2+7.5%) (nT31) (n =9) 
Transplant=7(78%) 
Group A (n=14) Group B 1n=17) 
Mean RVEF=12.5_+3.8% Mean RVEF=11.3:I:3.8% 
Transplant=14(100%) I 
I I 
Group B 1 (n=7) Group B= (n=10) 
Inotropes RVAD 
Mean RVEF=9.4+3.2% Mean RVEF=12.6+3.9% 
Transplant=5(71%) Transplant=4(40%) 
Fig. 1. Summary of Novacor LVAS recipient groups ac- 
cording to preimplantation RVEF and post-LVAS clinical 
course. Transplantation outcomes are shown. RVAD, 
Right ventricular-assist device. 
were discharged; one died while on support of 
septicemia from a pocket infection resulting from 
obesity when the device could not be placed below 
the rectus muscle, and another died while on sup- 
port of myocardial infarction. The remaining 31 
patients all had right ventricular dysfunction before 
LVAS insertion (mean RVEF 11.8% + 3.8%) and 
form the core group for analysis of factors predict- 
ing the need for right ventricle support. This group 
was further classified according to the ease of man- 
agement of the right ventricle after LVAS implan- 
tation. Group A (N = 14) required short-term 
(mean <7 days) of inotropic support. All underwent 
heart transplantation and were successfully dis- 
charged from hospital. Group B (AT = 17) required 
either high-dose inotropic support (group B1, N = 
7) or the addition of a right ventricular-assist device 
(group B2, N = 10). Five patients (71%) in group B 1 
underwent successful transplantation; two others 
died of cerebrovascular complications. Only four 
patients in group B2 (40%) survived to undergo 
transplantation; the remainder died of progressive 
multiorgan failure during LVAS support. 
Hemodynamie r sults. A summary of hemody- 
namic measurements in group A and B patients 
before and after LVAS implantation (at the time of 
sternal closure) are summarized in Fig. 2. Significant 
reductions were seen after LVAS implantation i
pulmonary capillary wedge pressure, pulmonary ar- 
tery mean pressure (36.0 vs 24.8 mm Hg; p < 
0.0001), and total pulmonary resistance for both 
groups. The total pulmonary resistance in group A 
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Fig. 2. Hemodynamic changes before (PreLVAS) and 
after (PostLVAS) Novacor implantation. NS, Not signifi- 
cant, 
was significantly ower (p < 0.04) than in group B 
after LVAS implantation. Accompanying these 
changes were significant elevations in cardiac index 
and RVEF. The cardiac index was similar in both 
groups after LVAS implantation; however, RVEF 
was significantly higher in group A after LVAS 
implantation (22.8% vs 16.2%; p < 0.0001). Al- 
though inotropic support required at sternal closure 
did not change significantly from pre-LVAS levels in 
either group, the degree of inotropic support was 
significantly higher in group B patients after LVAS 
(44.7 vs 18.8 IE; p < 0.004). There was a significant 
rise in the RVEF/IE ratio after LVAS implantation 
in group A but not in group B, and this ratio was 
significantly higher after LVAS implantation in 
group A (1.4) than in group B (0.5; p < 0.0001). 
There were no significant changes in central venous 
pressure after LVAS implantation i either group, 
nor were there differences between groups after 
LVAS insertion. No significant differences could be 
seen in hemodynamic response to LVAS between 
group B 1 and B z patients, and there were also no 
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differences in any of the immediate post-LVAS 
hemodynamic measurements between these groups. 
There were no significant differences between group 
A and B patients with respect to right-sided or 
left-sided filling pressures, mean pulmonary artery 
pressure, heart rate, cardiac index, total pulmonary 
resistance, or right ventricular ejection fraction be- 
fore LVAS implantation (Table I). Likewise, no 
differences were noted in the right ventricular end- 
diastolic or end-systolic volumes between these 
groups of patients before LVAS implantation. Pa- 
tients in group B had a greater level of inotropic 
support before LVAS than did those in group A 
(p < 0.02), and in fact the level of inotropic support 
was higher in group B~ than in group B 1 (p < 0.05). 
Finally, the RVEF/IE ratio was significantly ower in 
group B patients before LVAS (0.37) than in group 
A patients (0.56; p < 0.02). 
Clinical results. A summary of pre-LVAS clinical 
variables for the three groups is shown in Table II. 
No significant differences were seen between groups 
A and B1 or between groups B 1 and B 2 with respect 
to age, body surface area, gender, etiology of car- 
diomyopathy, or duration of support with inotropic 
agents or IABP before LVAS. Evidence of pulmo- 
nary edema on a chest radiograph was seen just 
before LVAS implantation i  53% of group B and 
14% of group A patients (p < 0.03). There was also 
a greater prevalence of this finding among patients 
who ultimately needed a right ventricular-assist 
device (60%) than among those who did not (43%); 
however this difference did not reach statistical 
significance. A significantly higher proportion of 
group B patients (41%) had a greater degree of 
mental impairment (mental score greater than or 
equal to 2) than among group A patients (7%) just 
before LVAS implantation (p < 0.04); however, 
groups B 1 and B 2 did not differ in this regard. The 
RVEF/IE ratio at the time of sternal closure ap- 
peared to be related to the pre-LVAS mental status 
(Fig. 3), with a lower ratio seen in patients with a 
mental status score of 2 or less (p < 0.004). The 
prevalence of fever (in the absence of infection) 
within 10 days before LVAS implantation was 
higher among group B than among group A patients 
(47% vs 14%) and was also higher among group B 2 
(70%) than among group B 1 (14%; p < 0.02). In 
patients with fever, the average time from last fever 
to LVAS implantation was significantly shorter 
among group B 2 patients (6 days) than among group 
B 1 patients (18 days; p < 0.02). Preimplantation 
hematologic, biochemical, and metabolic values are 
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Fig. 3. RVEF/IE ratio at sternal closure in group B 
patients. Averages are shown for patients with minimal or 
no mental dysfunction before LVAS implantation (score 0 
or 1) and for patients with moderate to severe mental 
dysfunction (score 2 or 3). 
shown in Table III. The peak creatinine levels were 
significantly higher in group B than in group A 
patients (2.1 _+ 0.7 vs 1.5 _+ 0.6 mg/dl) but did not 
differ between groups B a and B 2. Although the peak 
bilirubin level did not differ significantly between 
groups A and B, there was a trend toward higher 
preimplantation bilirubin levels in group B 2 than in 
group B 1 patients (3.3 _+ 2.9 vs 2.2 _+ 0.7 mg/dl). 
There were no significant differences in preimplan- 
tation hemoglobin levels, leukocyte counts, platelet 
counts, prothrombin times, and partial thrombo- 
plastin times between the groups of patients (A vs B; 
B 1 vs B2). Finally, mixed venous oxygen saturation 
immediately before LVAS implantation was signif- 
icantly lower in group B than in patients in group A 
(39.2% vs 52.5%; p < 0.001). 
One major complication seen after LVAS implan- 
tation was perioperative bleeding. Forty-three per- 
cent of group A and 88% of group B patients had 
perioperative bleeding that required blood product 
transfusion (p < 0.02). In 80% of the cases, this 
bleeding was caused by coagulopathy or diffuse 
bleeding from the outflow conduit and was not 
related to anastomotic or surgical technique. Al- 
though the difference was not statistically different, 
100% of group B 2 patients had perioperative bleed- 
ing complications, compared with 71% of the group 
B 1 patients. Blood product usage in the periopera- 
tive phase is shown in Table IV. Significantly greater 
amounts of erythrocytes (p < 0.01), fresh-frozen 
plasma (p < 0.05), platelets (p < 0.01), and cryo- 
precipitate (p < 0.05) were transfused into group B 
patients than into group A patients, and the trend 
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Table I. Pre-LVAS hemodynamic variables for LVAS recipients according to clinical group 
P P 
Group A Group B (group A vs group B) Group B 1 Group B 2 (group B1 vs group B2) 
Pulmonary capillary wedge pres- 26.4 _+ 5.9 25.7 _+ 6.1 NS 26.7 ± 7.93 25.1 ± 4.7 NS 
sure (mm Hg) 
Pulmonary artery mean pressure 36.8 _+ 8.1 37.6 ± 8.4 NS 9.4 _+ 12 36.3 + 5.1 NS 
(mm Hg) 
Central venous pressure (mm Hg) 16.6 __+ 7.5 16.2 ± 4.9 NS 18.4 ± 5 14.8 _+ 4.5 NS 
Heart rate (beats/min) 100 -- 16 110 _+ 21 NS 117 +_ 21 105 + 21 NS 
Cardiac index (L .  rain -1 - m -z) 1.9 _+ 0.2 2.2 _+ 0.6 NS 2.0 _+ 0.4 2.4 _+ 0.7 NS 
Total Pulmonary Resistance 782 _+ 201 745 _+ 340 NS 897 _+ 391 639 ± 272 NS 
(dynes. sec '  cm -5) 
RVEF (%) 12.5 ± 3.8 11.3 _+ 3.9 NS 9.4 _+ 3.2 12.6 ± 3.9 NS 
IE (/*g • kg -1 • rain 1) 23.6 _+ 5.7 32.7 +_ 12.6 <0.02 26.0 _+ 5.1 37.3 ± 14.3 <0.05 
RVEF/IE ratio 0.56 ± 0.27 0.37 ± 0.14 <0.02 0.36 _+ 0.08 0.38 - 0.18 NS 
Right ventricular end-diastolic 334 _+ 69 372 ± 128 NS 333 +_ 86 399 ± 149 NS 
volume (ml) 
Right ventricular end-diastolic 175 _+ 34 197 _+ 63 NS 183 _ 53 206 _+ 70 NS 
volume index (ml) 
Right ventricular end-systolic vol- 295 _+ 74 330 _+ 121 NS 298 _+ 841 352 _+ 141 NS 
ume (ml) 
Right ventricular end-systolic vol- 154 _+ 36 174 _+ 59 NS 163 +_ 52 181 ± 66 NS 
ume index (ml) 
NS, Not significant. 
Table II. Clinical variables for LVAS recipients according to clinical group 
P P 
Group A Group B (A vsB) Group B 1 Group B e (B 1 vsB2) 
N 14 17 7 10 
Age (yr) 45.5 ± 12.4 41.5 _+ 13.0 NS 40.3 _+ 9.8 42.2 _+ 15.4 NS 
Body surface area (m e) 1.9 _+ 0.2 1.9 ± 0.2 NS 1.8 _+ 0.1 1.9 + 0.2 NS 
Percent female 0 18 NS 28 10 NS 
Percent with idiopathic CM 64 82 NS 71 90 NS 
Percent with ischemic CM 36 18 NS 29 10 NS 
Percent with mental score ->2 7 41 <0.04 40 43 NS 
Percent with pulmonary edema before 14 53 <0.03 43 60 NS 
implantation 
Febrile days before implantation 27.0 _+ 41 9.6 _+ 8.1 NS 18 _+ 7.2 5.6 + 5.1 <0.02 
Percent with fever _<10 days before ira- 14 47 NS 14 70 <0.02 
plantation 
Preimplantation days of inotropic sup- 22.6 _+ 13.3 26.8 _+ 13.4 NS 22.6 ± 19 29.7 _+ 18 NS 
port 
Preimplantation days of IABP support 8.1 ± 9.2 10.9 _+ 11.2 NS 15 _+ 14 7.8 _+ 8.0 NS 
NS, Not significant. 
continued, with more of these blood products being 
required in group B 2 patients than in group B 1 
patients. Significant infections necessitating antibi- 
otics occurred in 14% of group A patients and 29% 
of group B patients (p not significant). In both 
groups of patients the pre-LVAS IABP support time 
was longer (mean 22.7 _ 14 days) in those who 
acquired an infection after LVAS implantation than 
in those who did not (mean 7.6 _+ 8 days;p < 0.002). 
Significant neurologic events occurred in 28% of 
group A and 12% of group B patients during LVAS 
support. Although there were no significant differ- 
ences noted between group A and group B patients 
with respect o weight of the heart at explantation 
(471 vs 515 gm), right ventricular wall thickness 
(0.64 vs 0.67 cm), left ventricular thickness (1.6 vs 
1.6 cm), and right ventricular myocyte hypertrophy, 
there was a significant difference in right ventricular 
wall thickness between group B 2 (0.83 cm) and 
group B 1 (0.44 cm) patients (p < 0.05). 
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Table III. Biochemical, hematologic, metabolic, and coagulation parameters for L VAS recipients according to 
clinical group 
P P 
Group A Group B (A vs B) Group B 1 Group B 2 (B 1 vs B2) 
Peak creatinine before implantation (mg/dl) 
Peak bilirubin before implantation (mg/dl) 
Preimplantation hemoglobin (gm/dl) 
Preimplantation leukocyte count (cells × 103/mm 3)
Preimplantation platelet count (cells × 103/mm s)
Mixed venous oxygen saturation (%) 
Prothrombin time (sec) 
Partial thromboplasdn time (sec) 
1.5 _+ 0.6 2.1 + 0.7 <0.02 2.1 ± 0.6 2.2 _+ 0.8 NS 
3.9 _+ 6.6 2.9 ± 2.3 NS 2.2 .+ 0.7 3.3 _+ 2.9 NS 
11.0 ± 2.1 10.9 -+ 1.4 NS 10.8 +_ L7 10.9 -+ 1.2 NS 
10.9 _+ 5.3 10.9 _+ 3.8 NS 9.3 ± 3.7 12.0 -+ 3.6 NS 
208 _+ 91 156 ± 82 NS 141 ± 39 167 -+ 103 NS 
52.5 _+ 7.4 39.2 _+ 10.4 <0.001 3714 ± 10.4 40.6 ± 10.8 NS 
13.6 ± 0.9 13.8 ± 1.8 NS 14.6 _+ 1.2 13.2 _+ 2.0 NS 
45.4 ± 12,6 48.9 +_ 11.4 NS 48.0 ± 15.8 49.5 ± 7.8 NS 
NS, Not significant. 
Table IV. Blood products transfused in L VAS recipients according to clinical group 
P P 
Blood products (units) Group A Group B (A vs B) Group B z Group B 2 (B 1 vs B2) 
Erythrocytes 5.1 ±_ 3.2 14.8 ± 12.5 <0.01 11.0 ± 13.4 17.4 _+ 11.8 NS 
Fresh-frozen plasma 5.9 --_ 3.3 14.2 + 14.6 <0.05 12.7 ± 11.8 15.2 ± 16.8 NS 
Platelets 11.1 + 9.6 28.8 + 20.9 <0.01 24.4 .+ 14.3 22.4 ± 24.9 NS 
Cryoprecipitate 9.4 ,+ 8.9 21.6 -- 20.7 <0.05 21.4 ± 18.6 22 _+ 23.1 NS 
Values represent only those amounts transfused during LVAS implantation operation and up to the point of any operation to place a right ventricular-assist 
device. NS, Not significant. 
Discussion 
Investigators have struggled to identify predictive 
factors for the development of right ventricular 
failure after the implantation of LVADs as a bridge 
to cardiac transplantation)' s, 9,11, 12 In patients who 
preferentially receive biventricular devices, the com- 
plications from multiorgan failure, lethal arrhyth- 
mias, and low cardiac output hat characterize the 
course of a patient in whom an inappropriate deci- 
sion for univentricular support was made are 
avoided. 13 Previous reports have examined the dif- 
ferences in hemodynamics and clinical variables 
among patients who received univentricular-assist 
or biventricular-assist devices; few, however, were 
able to prospectively follow the clinical performance 
of patients in whom LVADs alone were implanted 
who later required additional right ventricular sup- 
port. This study is unique in that attempts were 
made to initially support all patients with the Nova- 
cor LVAS alone, with only inotropic agents and 
pulmonary vasodilators used to support the right 
ventricle. Only after it was determined that LVAS 
output could not be maintained above a cardiac 
index of 2.0 L • min -1 • m -2 was a right ventricular- 
assist device inserted, so no preconceptions were 
made regarding the need for right ventricular sup- 
port on the basis of selected preimplantation vari- 
ables. The initial hemodynamic response to the 
LVAS confirmed previous findings in other reports, 
which showed that dramatic reductions occur in the 
pulmonary artery wedge and mean pulmonary ar- 
tery pressures, resulting in afterload reduction of the 
right ventricle (total pulmonary resistance) as an 
effect of decompression f the left ventricle by the 
LVAS. 
There were no clear differences in hemodynamics 
before LVAS implantation between our clinical 
groups of patients. AS in previous reports, right- 
sided and left-sided filling pressures, mean pulmo- 
nary artery pressure , heart rate, cardiac index, and 
right ventricular end-diastolic and end-systolic vol- 
umes did not differ between patients requiring min- 
imal support and those requiring maximal suppor t 
for the right ventricle) Only the preimplantation 
level of inotropic support differed significantly be- 
tween all three groups (A vs B; B 1 vs B2), with the 
highest preimplantation levels being seen in those 
that ultimately required a right ventricular-assist 
device. This trend was also reflected in the preim- 
plantation RVEF/IE ratio, which was higher in the 
group requiring minimal right ventricular support 
after LVAS. These findings are compatible with the 
premise that the patients who are most clinically 
compromised are those most likely to require biven- 
tricular support. 
Certain preimplantation clinical variables did ap- 
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pear different between patients who required mini- 
mal support (group A) and those who required 
more extensive right ventricular support (group 
B). Group B had more patients with mental impair- 
ment (41%) and with active pulmonary edema 
(53%), despite full medical management of heart 
failure. Preimplantation serum creatinine levels 
were higher and the mixed venous oxygen satura- 
tions were lower in this group than in group A. This 
is again consistent with the presumption that pa- 
tients who are more clinically compromised and 
have more marginal end-organ function tend to 
require more extensive right ventricular support 
after LVAS implantation. A differentiating variable 
between those who required extensive inotropic 
support (group B1) and those who required a right 
ventricular-assist device (Group B2) was the pres- 
ence of a fever within 10 days of LVAS implanta- 
tion. Seven of 10 patients in group B 2 had a fever 
before implantation, compared with one of seven in 
group B 1. Fever in the absence of infection is often 
seen in patients in the terminal stages of end:stage 
heart disease and is associated with elevated levels 
of tumor necrosis factor, a myocardial depressant. 14 
The difference in early perioperative blood transfu- 
sion requirements between group A and B patients 
is important to note because itwas caused by diffuse 
bleeding unrelated to obvious surgical problems 
before the need for a right ventricular-assist device. 
There was a positive correlation between the 
amount of blood transfused uring the operative 
period and the total pulmonary resistance at the 
time of sternal closure (Pearson product-moment 
correlation 0.60; p < 0.05). 
Analysis at autopsy or explantation failed to show 
major pathologic differences between hearts in the 
clinical groups except in thickness of the right 
ventricular wall. Patients who ultimately required 
biventricular support had a significantly thicker ight 
ventricular free walls than did those who did not 
need a right ventricular-assist device. It is well 
recognized that right ventricular coronary blood 
flow depends much more on perfusion pressure than 
does that in the left ventricle. Presumably right 
ventricular myocardial perfusion may be compro- 
mised in patients with a thickened right ventricular 
wall. Measurements made in this fashion may have 
less bearing on the clinical results because patho- 
logic examination of the heart after long periods of 
circulatory support may show that right ventricular 
wall thickness could have resolved with more ex- 
tended support and that indeed hypertrophy was 
more likely to be seen in patients who died early and 
did not have the benefit of such extended support 
and restructuring of the cardiac muscle. 
Our group of investigators and others have previ- 
ously shown that the principal effect of the LVAD is 
reduction of left ventricular pressure and thus of left 
atrial pressure, with consequent reduction of pulmo- 
nary artery pressure and right ventricular after- 
load.15, 16 Chow and Farrar 17 confirmed these pre- 
dictions in animal models, showing that the outcome 
with respect o right ventricular function was based 
on a complex interaction between afterload reduc- 
tion and loss of right ventricular contractility related 
to the degree of intraventricular septal shift.as' 19 We 
have performed sophisticated analyses of right ven- 
tricular performance with the relatively load-inde- 
pendent parameters derived from the pressure-vol- 
ume relationship obtained from transesophageal 
echocardiography and intraventricular pressure 
catheters. Contractility (end-systolic elastance) is 
impaired after LVAD implantation primarily as a 
result of loss of right ventricular function in the 
areas adjacent to the intraventricular septum, which 
shifts leftward dramatically. The beneficial effect 
of right ventricular afterload reduction, however, 
overwhelms any negative effects of reduced right 
ventricular contractility. 16In the face of adequately 
reduced right ventricular afterload, the right ventric- 
ular free wall actually appears to have improved 
fractional area change, despite uniformly depressed 
septal fractional area change. 2° We therefore may 
conclude that right ventricular performance after 
LVAS implantation is highly dependent on pulmo- 
nary vascular esistance and that any factors that 
produce an increase in pulmonary vascular esis- 
tance may result in right ventricular failure. 
One factor increasing pulmonary vascular esis- 
tance at the time of LVAD implantation may be 
cardiopulmonary b pass in this particularly ill group 
of patients. Reports have shown that cardiopulmo- 
nary bypass results in increased production of inter- 
leukins 6 and 8, with a concomitant activation of 
platelets, leukocytes, and complement. TM 22 Inflam- 
matory mediators rise and peak at 24 hours after 
bypass, along with complement C5a. Endotoxin 
levels have been shown to rise during cardiopulmo- 
nary bypass, 23 especially during nonpulsatile perfu- 
sion. During nonpulsatile cardiopulmonary b pass, 
splanchnic and hepatic blood flow is decreased, 
further impairing the ability of the liver to clear 
endotoxin, z4 In this series, cardiopulmonary b pass 
was performed with nonpulsatile perfusion by 
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means of a centrifugal pump. It is hypothesized that 
the interruption of pulmonary flow during bypass 
may be responsible for alterations in vasoreactivity 
in the pulmonary microvasculature because hista- 
mine, which normally causes the pulmonary micro- 
vasculature to dilate, results in vasoconstriction 
after cardiopulmonary bypass. 25 Patients with end- 
stage heart failure who have aseptic fevers and 
marginal end-organ function may already have ele- 
vated levels of endotoxin and cytokines. If cardio- 
pulmonary bypass amplifies these inflammatory me- 
diators, including endotoxin, it is possible that a 
coagulopathic state may accompany the operation, 
resulting in a need for more blood transfusions and 
further compromising the pulmonary microvascula- 
ture. Increased resistance to blood flow through the 
pulmonary vascular bed, in combination with the 
negative inotropic effects produced by these media- 
tors, could result in depressed right ventricular 
performance, obviating the main beneficial effect on 
the right ventricle of the LVAD, which is reduction 
of right ventricular afterload. 
In conclusion, this study demonstrated that pre- 
implantation hemodynamic values are insufficient 
predictors regarding which patients awaiting cardiac 
replacement can benefit from univentricular support 
alone. It suggests instead that clinical variables, 
which may in turn be dependent on the timing of 
device implantation, may play a more important role 
in determining the response of the right ventricle to 
LVAD support. In addition, perioperative factors 
that result in impairment of pulmonary blood flow 
or reduced perfusion of the right ventricle after 
LVAD implantation may also reduce the effective- 
ness of the LVAD in passive unloading of the right 
ventricle. Until fully elective LVAD implantation is 
carried out and these variables are normalized, true 
assessment of the outcome of univentricular support 
cannot be made, and the hemodynamic or biome- 
chanical variables that predict the need for biven- 
tricular support cannot be determined. 
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Discussion 
Dr. J. Donald Hill (San Francisco, Calif.). This is a 
difficult ype of clinical research because it is always done 
in an atmosphere of urgency and unstable patient condi- 
tion. I congratulate Kormos and colleagues on their 
careful adherence to their protocol. This report stands 
alone in its pursuit of differentiating data well into the 
interventional period of exploring the appropriate use of 
LVADs. This methodology adds measurably to the cred- 
ibility of the conclusions. 
The first thing that struck me on reviewing the manu- 
script was the similarity of the results and the conclusion 
to those of our recent report of the 213 patients treated 
with a Thoratec device with respect to prediction of 
requirements for right ventricular support after LVAD 
implantation. Indeed, preoperative hemodynamic pres- 
sure data, with the exception of cardiac index, were also 
not helpful. Oxygen delivery to the tissues, not pressure, is
the determining factor. 
As in this report, we also noted elevated creatinine as a 
predictor, along with decreased platelet counts, use of 
IABP, mechanical ventilation, and emergency implanta- 
tion, which occurred in 22% of the 139 patients receiving 
Thoratec BiVAD devices. Combining these two reports 
reinforces the importance of looking at the clinical con- 
dition of the patient as the differentiating factor for right 
ventricular support, rather than relying on hemodynamic 
data alone. 
I made one further observation regarding this report. 
Implantation of a right ventricular-assist device was done 
some 18 to 24 hours after initial operation, with a final 
survival of 40%. In the Thoratec data, in more than 75% 
Of the cases the decision to add a right ventricular-assist 
device was made intraoperatively, presumably because of 
its easy availability, with a resulting posttransplantation 
survival rate of 83%. 
I point this out to emphasize the references in this 
report o clinical status of the patient at the time of sternal 
closure as an important decision point in the need for a 
right ventricular-assist device. I support his observation 
100%, and in fact learned it from Dr. Kormos several 
years ago. 
I have several questions. One, this report is based on 40 
patients who were chosen at the outset for LVAD support 
alone. This is a subgroup of a larger group of patients with 
class IV heart failure necessitating transplantation. How 
large was the initial group, and how often did you not even 
consider LVAD use alone? 
Second, you emphasize the development of pulmonary 
vascular esistance during the operation as a prominent 
contributing cause of later right ventricular support re- 
quirements. Are you changing your operative procedure 
in any way to minimize the elevation of pulmonary 
vascular esistance, and if so, how? 
I think this is an exceptionally good report that really 
gets down to the nitty-gritty of a question that has been 
plaguing us for 10 years. This is another step in helping us 
to differentiate the problem. 
Dr. Kormos. I thank Dr. Hill for his comments and 
emphasize that the work that Hill and Farrar have done in 
the past 10 years has certainly motivated us to examine 
our patients more critically. It was the understanding of
the right and left ventricular interaction that Hill and 
Farrar clarified that allowed us to proceed with the work 
that you saw today. 
When we began this trial, our g0al was to use the 
LVAD to the exclusion of all other devices. In the past 
year, as we have learned more about he applicability and 
the limitations of the LVAD, we have in fact changed our 
strategy. In the original series of 43 patients, however, we 
used the LVAD alone and only used the right ventricular- 
assist device when it became obvious that cardiac index 
could not be supported by the LVAD either alone or in 
combination with in0tropic agents. 
We have now changed our strategy so that in subsets of 
patients who present acutely in cardiogeuic shock or in the 
very categories that you saw here with pulmonary edema 
and instability of end organs, we move to a device with a 
potential for biventricular use, which in our institution is 
the Thoratec ventricular-assist device. Although we begin 
by Using the LVAD alone, if by chest closure we see a 
pattern evolving with a low RVEF/IE ratio, we proceed 
with the addition of a Thoratec right ventricular-assist 
device. 
With respect o changes in pulmonary vascular esis- 
tance during operation, probably no factor has changed 
more than our ability to control perioperative bleeding. 
As can be seen from our report, we believe that severe 
perioperative bleeding did lead to instances of right 
ventricular dysfunction. We now use aprotinin in selected 
cases, but more importantly our methods of preclotting 
the inflow circuits before operation has changed. Since 
that time, less perioperative bleeding has been encoun- 
tered. Also inherent in this has been a subtle selection 
factor in that we now tend to choose patients for implan- 
tation who have far less deterioration i  their clinical 
course, and this probably has something to do with 
intraoperative blood loss and reduces the elevation of 
pulmonary resistance that we saw early in the series. 
Dr. Hachida (Tokyo, Japan). First, I congratulate you 
on your informative study and beautiful presentation. We 
are beginning a project with the Novacor LVAS in Japan. 
As you probably know, we do not have heart transplanta- 
tion in our country to the bridge, so we are going to be 
seeing long-term LVAS use. The data you presented are 
crucial information for us. 
I have two brief questions. First, you stated that you 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 4 
Kormos et aL 783  
found a difference in thickness of right ventricular f ee wall 
in group B 2. Does that imply that you looked at the histology 
of the right ventricle in these patients? It might be one of the 
predictors of right ventricular dysfunction after the implan- 
tation of the LVAS, which is a contraindication for the 
long-term use of the Novacor device. Second, what was the 
duration of right ventricular failure after the LVAS implan- 
tation? When did it occur? You used inotropic agents in 
group B1. When did you decide to use the right ventricular- 
assist device after the initial implantation? 
Dr. Kormos. I am not sure of the clinical significance of 
the finding of right ventricular hypertrophy. In many of 
these patients, perioperative hypotension tended to be 
seen very commonly, and as you know the right ventricle 
is so dependent on coronary perfusion pressure that it is 
possible that with hypotension a hypertrophic right ven- 
tricle performed less well. Other biopsy findings that we 
looked at included the percentage of fibrosis and other 
pathologic findings, although we did not find any signifi- 
cant differences between the groups with respect to those 
other pathologic findings. 
With respect o when right ventricular failure devel- 
oped, all of the patients reported on here had right 
ventricular-assist devices implanted if they needed them 
somewhere between 8 to 48 hours after LVAS implanta- 
tion. In retrospect, we probably could have made the 
diagnosis of right ventricular failure at the time of chest 
closure or at the time the patient left the operating room, 
but for study reasons we persisted with inotropic agents. I 
believe now that, as in Dr. Hill's findings, a more rapid 
institution of biventricular support probably certainly 
would have led to a higher survival and a higher trans- 
plantation rate for patients with severe biventricular fail- 
ure. 
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